The Infinium Global Research analyzes the Cancer Biomarkers Market over the period of 2018 to 2024. This report also provides detailed qualitative and quantitative analyses of the market dynamics, market size and future trends in global cancer biomarkers market. It will help a lot of decision makers to develop strategies and find new opportunities in the global markets of cancer biomarkers. The report covers market changing aspects including drivers, restraints, opportunities, and trends expected to encouragement the expansion of the cancer biomarkers market during the period. The global cancer biomarkers market is projected to grow at a CAGR of 10.5% over the forecast period of 2018-2024.
We are Now Including the Impact Analysis of the COVID-19 on this Premium Report and the Forecast Period of this Report shall be Revised to 2020-2026.
The Section on the Impact of COVID-19 on this Market is Included in the Report for Free. To Know More Request Sample of this Report: https://www.infiniumglobalresearch.com/reports/sample-request/1972
Cancer biomarkers are biological molecules found in blood, other body fluids, or tissues that are secreted by the cancerous tumor. It is a specific response of the body due to the presence of cancer. Cancer biomarkers include proteins, gene mutations, gene rearrangements, missing genes, and other molecules. Cancer biomarkers have many potential applications including risk assessment, screening, differential diagnosis, determination of prognosis, prediction of response to treatment, and monitoring of progression of the disease. It is used for the diagnosis and prognosis of various types of cancers including liver cancer, breast cancer, ovarian cancer, melanoma, pancreatic cancer, and many more. The use of cancer biomarkers to guide treatment can have both clinical and economic advantages.
Rising Occurrence of Several Types of Cancer Drives the Growth of Cancer Biomarkers Market
Cancer is a major public health problem worldwide. The rising occurrence of several types of cancer drives the growth of cancer biomarkers market. The Center for Disease Control and Prevention estimated that 22.9 million adults were diagnosed with cancer in 2016 in the U.S. The growing demand for cost-effective methods for cancer diagnosis boosts the cancer biomarkers market. According to the World Health Organization, the total annual economic cost of cancer was estimated at approximately USD 1.16 trillion. In addition, several countries have a strong government focus on healthcare costs and are implementing cost-effective health technology assessments that contribute to the growth of the cancer biomarkers market. The steady rise in the elderly population and the shift in behavioral patterns such as smoking, consumption of alcohol and lack of physical activity increase the risk of cancer.
However, the high capital investment required for the development and installation of laboratories curtails the growth of cancer biomarkers market. The safety and disposal considerations in specimen collection and storage are the major challenges for the growth of cancer biomarker market. Moreover, increasing awareness among healthcare professionals and rising demand for personalized medicine is anticipated to provide fruitful opportunities for market growth. Besides, the recent advancements in biologics technologies offer favorable growth opportunities for the biomarker-guided testing technologies for cancer treatment.
Ask Discount for the Latest Research Report @ https://www.infiniumglobalresearch.com/reports/request-discount/1972
North America is the Dominant Region in the Cancer Biomarkers Market
Geographically, North America is the dominant region in the cancer biomarkers market. The high rate of adoption of advanced medical technologies primarily drives the cancer biomarkers market in the North America region. The busy lifestyle increases the risk of cancer in the North America region, thus promoting the growth of the cancer biomarkers market in this region. Europe is the second largest region in the portable medical devices market as the countries in this region such as New Zealand, Ireland, and France have the highest cases of cancer. Asia Pacific regions are set to grow with an incredible pace in the cancer biomarkers market over the forecast period owing to the increasing aging population and the increasing occurrences of cancer in this region.
Cancer Biomarkers Market: Segmentation
The report on global cancer biomarkers market covers segments such as biomolecule type, cancer type, application, and end-users. On the basis of biomolecule type, the sub-markets include genetic, epigenetic, metabolic, and proteomic. On the basis of cancer type, the sub-markets include breast cancer, lung cancer, prostate cancer, colorectal cancer, stomach cancer, skin cancer, ovarian cancer, blood cancer, and others. On the basis of application, the sub-markets include diagnostics, prognostics, risk assessment, drug discovery and development, and others. On the basis of end-users, the sub-markets include hospitals, specialty centers, and academic and cancer research centers.
Browse Detailed TOC, Description, and Companies Mentioned in Report @ https://www.infiniumglobalresearch.com/healthcare-medical-devices/global-cancer-biomarkers-market
Cancer Biomarkers Market: Competitive Landscape
The report provides profiles of the companies in the market such as F. Hoffmann-La Roche Ltd, Abbott Laboratories, GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc, Becton, Dickinson and Company, Hologic, Inc., Genomic Health, Inc, Agilent Technologies, Inc., and Illumina, Inc.
Reasons to Buy this Report:
- Comprehensive analysis of global as well as regional markets of the cancer biomarkers.
- Complete coverage of all the product type and applications segments to analyze the trends, developments, and forecast of market size up to 2024.
- Comprehensive analysis of the companies operating in this market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and the latest developments of the company.
- Infinium Global Research- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.